COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #190 of 260
11/17 Late treatment study
Boari et al, Biosci. Rep., doi:10.1042/BSR20203455 (Peer Reviewed)
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study
Source   PDF   Share   Tweet
Retrospective 258 hospitalized patients in Italy showing lower mortality with HCQ treatment, unadjusted relative risk RR 0.455, p<0.001.
(data is in the supplementary appendix)

Boari et al., 11/17/2020, retrospective, Italy, Europe, peer-reviewed, 20 authors.
risk of death, 54.5% lower, RR 0.45, p < 0.001, treatment 41 of 202 (20.3%), control 25 of 56 (44.6%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.